Abnormal immunity and gene mutation in patients with severe hepatitis-B

Table 1 Status of T subgroups in the peripheral blood from patients with severe hepatitis (%, ^-x±s)

Group	n	CD3+	CD4+	CD8+	CD4+/CD8+
Control	20	0.60 ± 0.17	0.46 ± 0.05	0.33 ± 0.03	1.39 ± 0.18
AH	22	0.61 ± 0.06	0.38 ± 0.04a	0.33 ± 0.04	1.16 ± 0.20
FH	23	0.53 ± 0.07a	0.37 ± 0.03a	0.25 ± 0.06a	1.63 ± 0.30a
Mutation	12	0.15 ± 0.08	0.37 ± 0.12	0.16 ± 0.02b	2.35 ± 0.89b
Wild	11	0.56 ± 0.04	0.36 ± 0.04	0.28 ± 0.05	1.31 ± 0.18

^aP < 0.01 vs control;

^bP < 0.05 vs wild type. AH: Acute hepatitis, FH: Severe hepatitis.

Table 2 The serum levels of TNF-α, IFN-γ, IL-6, and IL-8 in patients with mutation in HBV DNA precore 1896 site (ng/L, ^-x±s)

Group	n	TNF-α	IFN-γ	IL-6	IL-8
Control	20	146.7 ± 9.4	65.0 ± 7.7	231.1 ± 16.4	110.2 ± 2.9
AH	22	220.6 ± 8.9	174.9 ± 12.0	285.8 ± 16.5	118.4 ± 5.1
FH	23	359.0 ± 17.2bc	234.7 ± 16.5bc	347.5 ± 31.3bd	181.1 ± 19.6a
Mutation	12	356.6 ± 18.1	273.4 ± 26.6e	387.7 ± 32.5e	173.5 ± 10.7
Wild	11	328.4 ± 14.6	207.8 ± 12.8	300.9 ± 16.3	173.1 ± 11.3

^aP < 0.05 vs control;

^bP < 0.01 vs control;

^cP < 0.05 vs AH;

^dP < 0.01 vs AH;

^eP < 0.05 vs wild strain. AH: Acute hepatitis, FH: Severe hepatitis.